HR Execs on the Move

CityVet™

www.cityvet.com

 
CityVet Veterinary Care - exceptional care with services include Boarding, Bathing, Grooming, Veterinary Care and Food & Supplies with locations in Dallas, TX, Houston, TX and Denver, CO.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cityvet.com
  • 3101, McKinney Avenue
    Dallas, TX USA 75204
  • Phone: 214.522.0030

Executives

Name Title Contact Details
Kimberly Burak
Chief People Officer Profile

Similar Companies

Blue Cross of Idaho

Since 1945, we`ve taken our role as an Idaho-based health insurance company to heart. While the health insurance marketplace has experienced lots of change in recent years, we haven`t. As a not-for-profit, we`re mission-driven to help connect Idahoans to quality healthcare that is affordable and build strong networks and services with our customers in mind. With an annual economic impact of $456 million (in 2016), we lead the state and industry in addressing the cost of healthcare and creating transformative customer experiences with information, tools and services. Ultimately, we aim to create a brighter future for all of us. All we need are customer-centric leaders like you.

Jewish Hospital and St. Mary's HealthCare, Inc.

Jewish Hospital & St. Mary's HealthCare, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Louisville, KY. To find more information about Jewish Hospital & St. Mary's HealthCare, Inc., please visit www.jhsmh.org

MedFolio

MedFolio is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kootenai Prosthetics and Orthotics

Kootenai Prosthetics & Orthotics is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.